Beta Bionics (NASDAQ:BBNX) Shares Gap Down Following Analyst Downgrade

Shares of Beta Bionics, Inc. (NASDAQ:BBNX) gapped down prior to trading on Friday after Bank of America downgraded the stock from a buy rating to a neutral rating. The stock had previously closed at $31.99, but opened at $22.75. Beta Bionics shares last traded at $21.34, with a volume of 1,589,063 shares.

Several other analysts have also commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Beta Bionics in a research note on Monday, December 29th. Lake Street Capital reiterated a “buy” rating and set a $35.00 price objective on shares of Beta Bionics in a research report on Wednesday, October 29th. Wall Street Zen upgraded Beta Bionics from a “strong sell” rating to a “hold” rating in a report on Saturday, November 1st. The Goldman Sachs Group upped their target price on Beta Bionics from $26.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $31.00 price target (up previously from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.20.

Insiders Place Their Bets

In other Beta Bionics news, Director Maria Palasis sold 1,406 shares of the firm’s stock in a transaction dated Friday, October 31st. The stock was sold at an average price of $26.91, for a total transaction of $37,835.46. Following the completion of the sale, the director directly owned 9,841 shares in the company, valued at approximately $264,821.31. This trade represents a 12.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the transaction, the chief financial officer owned 42,614 shares in the company, valued at $1,258,391.42. This represents a 31.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 35,302 shares of company stock valued at $1,036,449 in the last 90 days.

Hedge Funds Weigh In On Beta Bionics

A number of hedge funds have recently modified their holdings of BBNX. Eventide Asset Management LLC boosted its position in Beta Bionics by 0.5% during the third quarter. Eventide Asset Management LLC now owns 4,957,252 shares of the company’s stock valued at $98,500,000 after purchasing an additional 24,901 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Beta Bionics by 2.6% during the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock valued at $85,718,000 after buying an additional 110,000 shares during the last quarter. Soleus Capital Management L.P. grew its stake in shares of Beta Bionics by 12.5% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock valued at $55,622,000 after buying an additional 424,817 shares in the last quarter. Sands Capital Alternatives LLC increased its holdings in Beta Bionics by 15.0% in the second quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company’s stock worth $51,981,000 after buying an additional 466,331 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Beta Bionics by 213.5% during the third quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock valued at $44,036,000 after acquiring an additional 1,509,217 shares in the last quarter.

Beta Bionics Price Performance

The stock has a market capitalization of $939.49 million and a price-to-earnings ratio of -4.88. The stock’s 50 day simple moving average is $29.43 and its 200-day simple moving average is $22.24.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Tuesday, October 28th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. The business had revenue of $27.25 million for the quarter, compared to the consensus estimate of $23.92 million. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual?hormone modes.